UTHR UNITED THERAPEUTICS Corp stock chart & analysis
Conviction 44HealthcareScan · Fri, Nov 6, 2026UNITED THERAPEUTICS Corp (UTHR) closed at $562.02 (-0.65%) on Nov 6, 2026. Price is above its 50-day and above its 200-day moving average. RSI(14) 49, RS Rating 86, -8.5% from its 52-week high, +15.3% year to date. Sector: Healthcare · Pharmaceutical Preparations.
Financials as of Wed, Sep 30, 2026 · quarterly.
UTHR technical analysis
Trend
UTHR's moving averages are mixed — no clean uptrend or downtrend. It closed 5.2% above the 50-day ($533.99) and 5.1% above the 200-day ($534.47). ADX(14) at 21 points to a moderate trend. It meets 6 of 8 trend-template criteria.
Momentum
RSI(14) is 49, in the bearish half of its range. MACD crossed below its signal line one session ago. Its RS Rating of 86 puts its weighted 12-month performance ahead of about 86% of the US market.
Volume and volatility
Volume on the latest session ran 0.7× its 20-day average. It trades about $337.0M a day on average. ATR(14) is $18.97, 3.4% of price — its typical daily range. On-balance volume is trending up.
Key levels
The chart pattern's support is $496.46 and its resistance $612.11. The 52-week range is $444.04 to $614.23; price is 8.5% below the high and 26.6% above the low. The VWAP anchored at the 52-week high is $585.42, above price.
Performance
UTHR returned -6.1% (1 week), +5.5% (1 month), +6.1% (3 months), -0.5% (6 months), +25.6% (1 year), +15.3% (year to date).
About UNITED THERAPEUTICS Corp
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
Pharmaceutical Preparations · Listed 1999 · 1,400 employees
Recent news
- UNITED THERAPEUTICS Corp: Earnings resultsSEC EDGAR · Wed, Nov 4, 2026
- UNITED THERAPEUTICS Corp: Ownership stake amendedSEC EDGAR · Wed, Nov 4, 2026
Congress activity
Disclosed STOCK Act trades in UTHR · 3 recent
Insider activity
SEC Form 4 transactions in UTHR · open-market 9 sells
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
ROTHBLATT MARTINE A Chairperson & CEO · Common Stock · 2026-11-05 | Exercise | 9.5K | $1.1M | 2026-11-05 | 2026-11-06 |
ROTHBLATT MARTINE A Chairperson & CEO · Common Stock · 2026-11-05 | Sell | 320 | $180K | 2026-11-05 | 2026-11-06 |
ROTHBLATT MARTINE A Chairperson & CEO · Common Stock · 2026-11-05 | Sell | 520 | $293K | 2026-11-05 | 2026-11-06 |
ROTHBLATT MARTINE A Chairperson & CEO · Common Stock · 2026-11-05 | Sell | 720 | $407K | 2026-11-05 | 2026-11-06 |
ROTHBLATT MARTINE A Chairperson & CEO · Common Stock · 2026-11-05 | Sell | 462 | $262K | 2026-11-05 | 2026-11-06 |
ROTHBLATT MARTINE A Chairperson & CEO · Common Stock · 2026-11-05 | Sell | 156 | $89K | 2026-11-05 | 2026-11-06 |
ROTHBLATT MARTINE A Chairperson & CEO · Common Stock · 2026-11-05 | Sell | 280 | $159K | 2026-11-05 | 2026-11-06 |
ROTHBLATT MARTINE A Chairperson & CEO · Common Stock · 2026-11-05 | Sell | 562 | $321K | 2026-11-05 | 2026-11-06 |
ROTHBLATT MARTINE A Chairperson & CEO · Common Stock · 2026-11-05 | Sell | 585 | $334K | 2026-11-05 | 2026-11-06 |
ROTHBLATT MARTINE A Chairperson & CEO · Common Stock · 2026-11-05 | Sell | 375 | $215K | 2026-11-05 | 2026-11-06 |
SEC filings
EDGAR filings in UTHR · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.